Facio Therapies announced today that it had successfully completed an equity financing round with proceeds of €8M (approximately A$12.5M; C$12M; US$9M). FSHD Spain and 30 other members of the FSHD community newly invested alongside existing investors, including Facio’s drug discovery partner, Evotec. Facio will use these funds to expand its recently announced in vivoproof of principle and to advance selected lead candidates towards clinical studies.
The key event in FSHD is the undue production of the DUX4 protein in skeletal muscle. DUX4 sets in motion a cascade of biochemical events that eventually result in the devastating effects of FSHD. In people without FSHD, the production of DUX4 in skeletal muscle is repressed by regulatory mechanisms. Facio’s single goal is to develop therapies that restore this repression as much as possible. Facio is the only one in the FSHD field with a fully automated, high-throughput screening platform based on quantifying the DUX4 protein in unadulterated (“primary”) FSHD-affected muscle cells. Recently, Facio delivered the first-ever proof of principle in FSHD using one of its lead candidates in a unique FSHD-relevant animal model (“in vivo”).
Three FSHD-affected families founded Facio in September 2014. Since then, Facio has raised over €16M in equity. About 77% of that amount has been invested by members of the FSHD community. Facio’s investor base now spans 14 countries around the world. FSHD Spain became the fifth FSHD foundation to invest in Facio, joining Amis FSH(France), FSHD Canada, FSHD Global Research (Australia), and the FSHD Stichting (Netherlands).
“The success of this financing round is not only that we reached our goal of raising €8 million,” said Facio’s Chairman, Kees van der Graaf. “The success is just as well that Facio’s message resonates with an ever-growing number of FSHD-affected families across the globe. We, people living with FSHD, don’t have to wait and hope for a breakthrough to happen. We’re breaking through to therapy ourselves. That is Facio’s message.”
https://www.hollandbio.nl/wp-content/uploads/2018/01/logo3.png00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2018/01/logo3.pngHollandBIO2018-11-16 17:17:062018-11-20 17:18:26Facio raises €8M in equity financing
Schrijf je in voor de HollandBIO Weekly
HollandBIO is de belangenvereniging van biotech bedrijven in Nederland. Samen werken we aan ons toekomstideaal: een maatschappij waarin biotechnologie maximaal bijdraagt aan gezondheid, duurzaamheid en economische groei.
Laan van Nieuw Oost-Indië 131-133
2593 BM Den Haag
Laan van Nieuw Oost-Indië 131 E
2593 BM Den Haag